Refarmed Chemicals is proud to present its esteemed pharmaceutical compound, Butamirate Citrate, an integral antitussive agent designed to alleviate discomfort in patients suffering from dry, unproductive coughs. Our Butamirate Citrate is an optimal choice for those grappling with upper respiratory tract infections, bronchitis, pneumonia, and even asthma, providing relief from persistent coughing that often accompanies these conditions. Crafted with meticulous attention to quality, our Butamirate Citrate appears as a white to yellowish powder with a slightly waxy texture, assuring ease of incorporation into various dosage forms. Its chemical identity is confirmed through rigorous testing, including the citrate and IR tests, maintaining a high level of purity and performance. The compound exhibits excellent solubility, being freely soluble in water and ethanol (96%), which ensures flexibility in formulation. Adhering to the gold standard of production, Butamirate Citrate holds GMP certification and is characterized by a precise pH range of 3.5 to 4.0. Our commitment to safety and efficacy is evidenced by the thorough analysis that guarantees an assay value between 98.0% - 102.0%, with minimal impurities. Heavy metals content is strictly controlled to ensure patient safety, and residual solvents such as Isopropanol, MTBE, Isopropyl ether, and Toluene are meticulously regulated. Our Butamirate Citrate operates by targeting the cough center in the medulla oblongata to effectively suppress cough reflexes, without reliance on opioids. This action provides a duration of relief for 4-8 hours, allowing for a more comfortable recovery process for the patient. It is suitable for adults and children over the age of 6, with dosage adjustments available to accommodate individual patient responses and tolerability. In conclusion, Refarmed Chemicals' Butamirate Citrate stands as a testament to our dedication to delivering pharmaceutical ingredients of the highest caliber. Our product not only meets the robust demands of the pharmaceutical industry but also provides a critical component for the formulation of efficacious cough suppressants that cater to a wide range of patients.

Products still subject to third-party patent protection might be available solely for R&D purposes.

Benserazide Hydrochloride, offered under REFARMED CHEMICALS—a subsidiary of the DKSH Group—is an essential pharmaceutical ingredient tailored for the robust demands of the medical industry. Specifically formulated for the management of Parkinson’s disease, Benserazide Hydrochloride serves as a monoamine oxidase B (MAO-B) inhibitor. When synergistically combined with levodopa, it not only amplifies the efficacy of the treatment but also mitigates associated side effects such as nausea, enhancing the quality of life for patients suffering from this neurodegenerative condition. Our Benserazide Hydrochloride emerges as a white to off-white crystalline powder, a testament to its purity and quality. The compound exhibits admirable water solubility, ensuring ease of formulation and bioavailability. Its molecular identity, C10H14N2O3·HCl, with a molecular weight of 234.7 g/mol, aligns with rigorous pharmaceutical prerequisites. Our product delivers through a strict adherence to quality with an assay value ranging from 98.5% to 101.0%, guaranteeing a high-caliber substance with minimal impurity content. REFARMED CHEMICALS prioritizes safety and compliance, validating Benserazide Hydrochloride's authenticity with the IR and Chlorides test among others, and acknowledges the product’s conscientious solubility in water and minimal solubility in anhydrous ethanol. We maintain stringent control on residual solvents, ensuring ethanol levels remain below 5000 ppm and methanol below 3000 ppm. Administered orally, this pharmaceutical agent's dosage is contingent upon individual patient needs and medical recommendations, subject to professional healthcare guidance. Despite its profound benefits, it should be noted that Benserazide Hydrochloride is contraindicated for patients with severe hepatic or renal impairments and requires cautious use in patients with a history of cardiovascular diseases, orthostatic hypotension, or psychiatric conditions. Interaction with opioids and antidepressants necessitates careful management. Upholding the highest standards, our product is compliant with Good Manufacturing Practice (GMP) and holds the Certificate of Suitability (CEP)—a rigorous certification ensuring consistency in high-quality production for our corporate customers. With REFARMED CHEMICALS, you are guaranteed a product that not only addresses the therapeutic needs but also embodies the precision and reliability sought after in the pharmaceutical industry.

Products still subject to third-party patent protection might be available solely for R&D purposes.

Refarmed Chemicals takes pride in providing the pharmaceutical industry with high-quality Ticlopidine Hydrochloride, an essential antiplatelet medication used to prevent strokes and other significant blood clots in patients who have experienced a stroke or transient ischemic attack (TIA). Manufactured under stringent GMP certification, our Ticlopidine Hydrochloride is presented in tablet form, with a strength of 250 mg ensuring consistent dosing and efficacy. Our Ticlopidine Hydrochloride acts by hindering platelet function, thereby diminishing the aggregation essential to blood clot formation. This preventive approach serves as a critical intervention in the management of clot-related disorders, significantly improving patient outcomes. Physicians typically recommend a starting dose of 250 mg administered twice daily, emphasizing that food intake during administration reduces gastrointestinal discomfort. Monitoring patient response allows for personalized treatment adjustments to optimize therapeutic benefits while considering safety profiles. As with all pharmaceuticals, we duly note possible side effects, ranging from mild gastrointestinal issues to less common, yet more severe reactions like neutropenia or liver impairment. This necessitates caution in prescribing to populations with liver disease, a history of bleeding disorders, or inflammatory bowel disease. Continuous patient monitoring and drug interaction vigilance are paramount, especially concerning commonly used medications such as aspirin and warfarin. Compliant storage conditions entail keeping the Ticlopidine Hydrochloride tablets at room temperature (15°C to 30°C), shielded from light and moisture to maintain product integrity. Ticlopidine Hydrochloride is supplied as a generic medication, ensuring affordability without compromising quality. Embracing our commitment to patient safety and treatment adherence, we underline the significance of medical guidance before initiating or discontinuing use, with particular respect to special populations like pregnant or breastfeeding women. Rest assured, our partnership with the DKSH Group underlines a shared vision for growth and delivery of quality healthcare solutions that spans across Asia and beyond, cementing our position as a trusted supplier in the pharmaceutical landscape.

Products still subject to third-party patent protection might be available solely for R&D purposes.

Tulobuterol base is a high-grade bronchodilator, primarily used for managing respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). This potent pharmaceutical ingredient is engineered to target and activate beta-2 adrenoreceptors in the airways, resulting in the relaxation of bronchial smooth muscles and effective bronchodilation. Refarmed Chemicals, a key player in the pharmaceutical industry and now part of the DKSH Group, manufactures Tulobuterol base with a commitment to excellence, as evidenced by compliance with EU GMP certifications and stringent quality controls. The product is presented as a white crystalline powder, with its consistency and purity validated by a comprehensive series of tests including IR, HPLC, and TLC tests. At the onset of use, Tulobuterol base exhibits rapid action within 5-15 minutes and sustains its therapeutic effect for up to 6 hours. Its main application is for the relief and prevention of bronchospasm in patients, thereby improving airway obstruction and lung function. Administered via an aerosol inhaler or nebulizer, dosage and frequency are tailored to individual patient needs and disease severity. The product's reliability is reinforced by its exhaustive assay, showing a 98.5% - 102% active ingredient range, with controlled levels of impurities and residual solvents. Safety is a core aspect of Tulobuterol base's design, having been tested for adverse components. Common side effects may include tachycardia and nervousness, among others. Caution is advised for patients with cardiovascular disease, hypertension, and diabetes. Tulobuterol base is contraindicated for individuals with hypersensitivity to beta-adrenergic agonists, those with thyrotoxicosis or tachyarrhythmias, and it is not recommended for use in children under 12 years of age. As with all medications, potential drug interactions need to be considered, notably with beta-blockers and other beta-adrenergic agonists. This product serves as a testament to Refarmed Chemicals' dedication to providing superior pharmaceutical materials. Through their integration with DKSH, they strive to deliver growth in Asia and beyond, ensuring the availability of quality medical compounds to healthcare providers and patients worldwide.

Products still subject to third-party patent protection might be available solely for R&D purposes.